Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,142,756
  • Shares Outstanding, K 98,969
  • Annual Sales, $ 248,070 K
  • Annual Income, $ -63,560 K
  • 60-Month Beta 2.34
  • Price/Sales 36.08
  • Price/Cash Flow N/A
  • Price/Book 45.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.01
  • Number of Estimates 4
  • High Estimate 0.03
  • Low Estimate -0.05
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +94.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.87 +36.76%
on 10/25/19
93.13 -0.33%
on 11/22/19
+21.01 (+29.26%)
since 10/22/19
3-Month
67.87 +36.76%
on 10/25/19
97.71 -5.01%
on 08/23/19
-3.78 (-3.91%)
since 08/22/19
52-Week
28.73 +223.08%
on 11/23/18
98.70 -5.96%
on 08/21/19
+63.79 (+219.74%)
since 11/21/18

Most Recent Stories

More News
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology

Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO)...

NVCR : 93.50 (+1.21%)
NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 93.50 (+1.21%)
Novocure Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Novocure Ltd. (NASDAQ: ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 31, 2019 at 8:00 AM Eastern...

NVCR : 93.50 (+1.21%)
Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

--First quarter ever of positive net income with $0.02 in earnings per share

NVCR : 93.50 (+1.21%)
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

Style Box ETF report for FNY

FNY : 46.69 (unch)
IWP : 148.72 (+0.22%)
PODD : 178.26 (+1.41%)
FCN : 107.16 (-0.96%)
NVCR : 93.50 (+1.21%)
IJK : 229.88 (+0.21%)
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

--NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years

NVCR : 93.50 (+1.21%)
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

--NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years

NVCR : 93.50 (+1.21%)
NVE Schedules Conference Call on Second-Quarter Results

NVE Corporation (Nasdaq: NVEC) announced that it plans to release its financial results for the quarter and six months ended September 30, 2019 on Wednesday, October 23, 2019 after the close of the Nasdaq...

NVCR : 93.50 (+1.21%)
NVEC : 63.49 (+0.78%)
Novocure to Report Third Quarter 2019 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2019 on Thursday, October 31, 2019, before the U.S. financial markets open. Novocure management will...

NVCR : 93.50 (+1.21%)
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting

--Highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and the first presentation of in vitro data combining treatment with Tumor...

NVCR : 93.50 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The current trending strength of the market is Strong.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 94.03
1st Resistance Point 93.21
Last Price 93.50
1st Support Level 90.85
2nd Support Level 89.31

See More

52-Week High 98.70
Last Price 93.50
Fibonacci 61.8% 71.97
Fibonacci 50% 63.71
Fibonacci 38.2% 55.46
52-Week Low 28.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar